NCT04636762View on ClinicalTrials.gov

A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2022

Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
PROCEDURE

Radiation Therapy

Thoracic Radiation Dose: 3Gy, QD, total dose: 30-45Gy; Particpants with brain metastases：metastatic lesions≤3:whole brain radiotherapy with local simultaneous PGTV:50Gy/10F；metastatic lesions\>3:whole brain radiotherapy PTV:30Gy/10F.

Trial Locations (2)

410000

Hunan cancer hospital, Changsha

the second Xiangya hospital, Changsha

All Listed Sponsors
collaborator

Hunan Cancer Hospital

OTHER

lead

Second Xiangya Hospital of Central South University

OTHER

NCT04636762 - A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | Biotech Hunter | Biotech Hunter